In a report issued yesterday, analyst Liana Moussatos of Wedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ:PCRX) with a $110 price target, following strong July Symphony Health …
In a research report released today, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Pacira Pharmaceuticals (PCRX) and a price target of $109.00 a share, representing a potential upside of …
